Advancing mechanistic understanding and biomarker development in amyotrophic lateral sclerosis

References

• Hardiman O, Al-Chalabi A, and Chio A, et al. Amyotrophic lateral sclerosis. Nat Rev Dis Primers. 2017;5 (3):7071.
   Google Scholar
• Renton AE, Chiò A, and Traynor BJ. State of play in amyotrophic lateral sclerosis genetics. Nat Neurosci. . 2014;17 (1):17–23.
   PubMed Web of Science ®Google Scholar
• Al-Chalabi A, Fang F, and Hanby MF, et al. An estimate of amyotrophic lateral sclerosis heritability using twin data. J Neurol Neurosurg Psychiatry . 2010;81(12):1324–1326.
   PubMed Web of Science ®Google Scholar
• van Blitterswijk M, van Es MA, and Hennekam EA, et al. Evidence for an oligogenic basis of amyotrophic lateral sclerosis. Hum Mol Genet . 2012;21(17):3776–3784.
   PubMed Web of Science ®Google Scholar
• Zou ZY, Zhou ZR, and Che CH, et al. Genetic epidemiology of amyotrophic lateral sclerosis: a systematic review and meta-analysis. J Neurol Neurosurg Psychiatry . 2017;88(7):540–549.
   PubMed Web of Science ®Google Scholar
• Taylor JP, Brown RHJ, and Cleveland DW. Decoding ALS: from genes to mechanism. Nature. . 2016;539(7628):197–206.
   PubMed Web of Science ®Google Scholar
• Talbot K, Feneberg E, Scaber J, et al. Amyotrophic lateral sclerosis: the complex path to precision medicine. J Neurol. 2018;265(10):2454–2462.
   PubMed Web of Science ®Google Scholar
• Al-Chalabi A, Calvo A, and Chio A, et al. Analysis of amyotrophic lateral sclerosis as a multistep process: a population-based modelling study. Lancet Neurol . 2014;13(11):1108–1113.
   PubMed Web of Science ®Google Scholar
• Neumann M, Sampathu DM, and Kwong LK, et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science . 2006;314(5796):130–133.
   PubMed Web of Science ®Google Scholar
• Aebersold R, Mann M. Mass-spectrometric exploration of proteome structure and function. Nature. 2016;537(7620):347–355.
   PubMed Web of Science ®Google Scholar
• Laferrière F, Maniecka Z, Pérez-Berlanga M, et al. TDP-43 extracted from frontotemporal lobar degeneration subject brains displays distinct aggregate assemblies and neurotoxic effects reflecting disease progression rates. Nat Neurosci. 2019;22(1):65–77.
   PubMed Web of Science ®Google Scholar
• Feneberg E, Gray E, and Ansorge O, et al. Towards a TDP-43-Based Biomarker for ALS and FTLD. Mol Neurobiol . 2018; . ;55(10):7789–7801.
   PubMed Web of Science ®Google Scholar
• Igaz LM, Kwong LK, Xu Y, et al. Enrichment of C-terminal fragments in TAR DNA-binding protein-43 cytoplasmic inclusions in brain but not in spinal cord of frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Am J Pathol. 2008;173(1):182–194.
   PubMed Web of Science ®Google Scholar
• Alonso R, Pisa D, Marina AI, et al. Evidence for fungal infection in cerebrospinal fluid and brain tissue from patients with amyotrophic lateral sclerosis. Int J Biol Sci. 2015;11(5):546–558.
   PubMed Web of Science ®Google Scholar
• Vassileff N, Vella LJ, Rajapaksha H, et al. Revealing the proteome of motor cortex derived extracellular vesicles isolated from amyotrophic lateral sclerosis Human Postmortem Tissues. Cells. 2020;9(7):1709.
   Web of Science ®Google Scholar
• Iridoy MO, Zubiri I, and Zelaya MV , et al. Neuroanatomical quantitative proteomics reveals common pathogenic biological routes between amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). Int J Mol Sci. 2019; 20(1):4 .
   Web of Science ®Google Scholar
• Conti A, Riva N, Pesca M, et al. Increased expression of Myosin binding protein H in the skeletal muscle of amyotrophic lateral sclerosis patients. Biochim Biophys Acta - Mol Basis Dis. 2014;1842(1):99–106.
   PubMed Web of Science ®Google Scholar
• Elf K, Shevchenko G, Nygren I, et al. Alterations in muscle proteome of patients diagnosed with amyotrophic lateral sclerosis. J Proteomics. 2014;108:55–64.
   PubMed Web of Science ®Google Scholar
• Kametani F, Obi T, and Shishido T, et al. Mass spectrometric analysis of accumulated TDP-43 in amyotrophic lateral sclerosis brains. Sci Rep. 2016;6(1).
   PubMedGoogle Scholar
• Feneberg E, Charles PD, and Finelli MJ, et al. Detection and quantification of novel C-terminal TDP-43 fragments in ALS-TDP. Brain Pathol. 2020; 31(4):e129 ;
   Web of Science ®Google Scholar
• Nonaka T, Kametani F, Arai T, et al. Truncation and pathogenic mutations facilitate the formation of intracellular aggregates of TDP-43. Hum Mol Genet. 2009;18(18):3353–3364.
   PubMed Web of Science ®Google Scholar
• Tomé SO, Vandenberghe R, Ospitalieri S, et al. Distinct molecular patterns of TDP-43 pathology in Alzheimer’s disease: relationship with clinical phenotypes. Acta Neuropathol Commun. 2020;8(1). DOI:https://doi.org/10.1186/s40478-020-00934-5.
   Google Scholar
• Pobran TD, Yang D, Mackenzie IRA, et al. Aptamer-based enrichment of TDP-43 from human cells and tissues with quantification by HPLC-MS/MS. J Neurosci Methods. 2021;363:109344.
   PubMed Web of Science ®Google Scholar
• Strong MJ, Strong WL, Jaffe H, et al. Phosphorylation state of the native high-molecular-weight neurofilament subunit protein from cervical spinal cord in sporadic amyotrophic lateral sclerosis. J Neurochem. 2001;76(5):1315–1325.
   PubMed Web of Science ®Google Scholar
• Umoh ME, Dammer EB, and Dai J, et al. A proteomic network approach across the ALS-FTD disease spectrum resolves clinical phenotypes and genetic vulnerability in human brain. EMBO Mol Med. 2018;10(1):48–62.
   PubMed Web of Science ®Google Scholar
• Engelen-Lee J, Blokhuis AM, Spliet WGM, et al. Proteomic profiling of the spinal cord in ALS: decreased ATP5D levels suggest synaptic dysfunction in ALS pathogenesis. Amyotroph Lateral Scler Front Degener. 2017;18(3–4):210–220.
   PubMed Web of Science ®Google Scholar
• Liu D, Liu C, and Li J, et al. Proteomic analysis reveals differentially regulated protein acetylation in human amyotrophic lateral sclerosis spinal cord. PLoS One. 2013; 8(12):e779
   Web of Science ®Google Scholar
• Oeckl P, Weydt P, and Thal DR, et al. Proteomics in cerebrospinal fluid and spinal cord suggests UCHL1, MAP2 and GPNMB as biomarkers and underpins importance of transcriptional pathways in amyotrophic lateral sclerosis. Acta Neuropathol. 2020;139(1):119–134.
   PubMed Web of Science ®Google Scholar
• Volkening K, Keller BA, and Leystra-Lantz C, et al. RNA and Protein Interactors with TDP-43 in Human Spinal-Cord Lysates in Amyotrophic Lateral Sclerosis. J Proteome Res. 2018 17(4) 1712–29 ;
   Web of Science ®Google Scholar
• Hanrieder J, Ekegren T, Andersson M, et al. MALDI imaging of post-mortem human spinal cord in amyotrophic lateral sclerosis. J Neurochem. 2013;124(5):695–707.
   PubMed Web of Science ®Google Scholar
• Ekegren T, Hanrieder J, Aquilonius SM, et al. Focused proteomics in post-mortem human spinal cord. J Proteome Res. 2006;5(9):2364–2371.
   PubMed Web of Science ®Google Scholar
• Feneberg E, Gordon D, Thompson AG, et al. An ALS-linked mutation in TDP-43 disrupts normal protein interactions in the motor neuron response to oxidative stress. Neurobiol Dis. 2020;144:105050.
   PubMed Web of Science ®Google Scholar
• Freibaum BD, Chitta RK, and High AA, et al. Global analysis of TDP-43 interacting proteins reveals strong association with RNA splicing and translation machinery. J Proteome Res. 2010;9(2):1104–1120.
   PubMed Web of Science ®Google Scholar
• Davis SA, Itaman S, Khalid-Janney CM, et al. TDP-43 interacts with mitochondrial proteins critical for mitophagy and mitochondrial dynamics. Neurosci Lett. 2018;678:8–15.
   PubMed Web of Science ®Google Scholar
• Blokhuis AM, Koppers M, and Groen EJN, et al. Comparative interactomics analysis of different ALS-associated proteins identifies converging molecular pathways. Acta Neuropathol. 2016;132(2):175–196.
   PubMed Web of Science ®Google Scholar
• Kawaguchi T, Rollins MG, Moinpour M, et al. Changes to the TDP-43 and FUS Interactomes Induced by DNA Damage. J Proteome Res. 2020;19(1):360–370.
   PubMed Web of Science ®Google Scholar
• Kamelgarn M, Chen J, Kuang L, et al. Proteomic analysis of FUS interacting proteins provides insights into FUS function and its role in ALS. Biochim Biophys Acta - Mol Basis Dis. 2016;1862(10):2004–2014.
   Web of Science ®Google Scholar
• Sun S, Ling SC, and Qiu J, et al. ALS-causative mutations in FUS/TLS confer gain and loss of function by altered association with SMN and U1-snRNP. Nat Commun. 2015; 6:6171 .
   PubMed Web of Science ®Google Scholar
• Wang T, Jiang X, Chen G, et al. Interaction of amyotrophic lateral sclerosis/frontotemporal lobar degeneration-associated fused-in-sarcoma with proteins involved in metabolic and protein degradation pathways. Neurobiol Aging. 2015;36(1):527–535.
   PubMed Web of Science ®Google Scholar
• Basso M, Samengo G, Nardo G, et al. Characterization of detergent-insoluble proteins in ALS indicates a causal link between nitrative stress and aggregation in pathogenesis. PLoS One. 2009;4(12):e8130.
   PubMed Web of Science ®Google Scholar
• Shaw BF, Lelie HL, Durazo A, et al. Detergent-insoluble aggregates associated with amyotrophic lateral sclerosis in transgenic mice contain primarily full-length, unmodified superoxide dismutase-1. J Biol Chem. 2008;283(13):8340–8350.
   PubMed Web of Science ®Google Scholar
• Une M, Yamakawa M, Watanabe Y, et al. SOD1-interacting proteins: roles of aggregation cores and protein degradation systems. Neurosci Res. 2021;170:295–305.
   PubMed Web of Science ®Google Scholar
• Hans F, Eckert M, Von Zweydorf F, et al. Identification and characterization of ubiquitinylation sites in TAR DNA-binding protein of 43 kDa (TDP-43). J Biol Chem. 2018;293(41):16083–16099.
   PubMed Web of Science ®Google Scholar
• Monahan Z, Ryan VH, Janke AM, et al. Phosphorylation of the FUS low-complexity domain disrupts phase separation, aggregation, and toxicity. EMBO J. 2017;36(20):2951–2967.
   PubMed Web of Science ®Google Scholar
• Cohen TJ, Hwang AW, and Restrepo CR, et al. An acetylation switch controls TDP-43 function and aggregation propensity. Nat Commun. 2015;6.
   Web of Science ®Google Scholar
• Tanikawa C, Ueda K, Suzuki A, et al. Citrullination of RGG Motifs in FET Proteins by PAD4 Regulates Protein Aggregation and ALS Susceptibility. Cell Rep. 2018;22(6):1473–1483.
   PubMed Web of Science ®Google Scholar
• Niikura T, Kita Y, Abe Y. SUMO3 modification accelerates the aggregation of ALS-Linked SOD1 mutants. PLoS One. 2014;9(6):e101080.
   PubMed Web of Science ®Google Scholar
• Bruijn LI, Becher MW, Lee MK, et al. ALS-linked SOD1 mutant G85R mediates damage to astrocytes and promotes rapidly progressive disease with SOD1-containing inclusions. Neuron. 1997;18(2):327–338.
   PubMed Web of Science ®Google Scholar
• Gertsman I, Wuu J, and McAlonis-Downes M, et al. An endogenous peptide marker differentiates SOD1 stability and facilitates pharmacodynamic monitoring in SOD1 amyotrophic lateral sclerosis. JCI Insight. 2019;4(10). .
   PubMed Web of Science ®Google Scholar
• Shi Y, Rhodes NR, Abdolvahabi A, et al. Deamidation of asparagine to aspartate destabilizes Cu, Zn superoxide dismutase, accelerates fibrillization, and mirrors ALS-linked mutations. J Am Chem Soc. 2013;135(42):15897–15908.
   PubMed Web of Science ®Google Scholar
• Hutten S, Dormann D. RAN translation down. Nat Neurosci. 2019;22(9):1379–1380.
   PubMed Web of Science ®Google Scholar
• Radwan M, Ang CS, Ormsby AR, et al. Arginine in C9ORF72 dipolypeptides mediates promiscuous proteome binding and multiple modes of toxicity. Mol Cell Proteomics. 2020;19(4):640–654.
   PubMed Web of Science ®Google Scholar
• Moens TG, Niccoli T, Wilson KM, et al. C9orf72 arginine-rich dipeptide proteins interact with ribosomal proteins in vivo to induce a toxic translational arrest that is rescued by eIF1A. Acta Neuropathol. 2019;137(3):487–500.
   PubMed Web of Science ®Google Scholar
• Hartmann H, Hornburg D, Czuppa M, et al. Proteomics and C9orf72 neuropathology identify ribosomes as poly-GR/PR interactors driving toxicity. Life Sci Alliance. 2018;1(2):e201800070.
   PubMed Web of Science ®Google Scholar
• Kanekura K, Yagi T, Cammack AJ, et al. Poly-dipeptides encoded by the C9ORF72 repeats block global protein translation. Hum Mol Genet. 2016;25(9):1803–1813.
   PubMed Web of Science ®Google Scholar
• May S, Hornburg D, Schludi MH, et al. C9orf72 FTLD/ALS-associated Gly-Ala dipeptide repeat proteins cause neuronal toxicity and Unc119 sequestration. Acta Neuropathol. 2014;128(4):485–503.
   PubMed Web of Science ®Google Scholar
• Cooper-Knock J, Walsh MJ, and Higginbottom A, et al. Sequestration of multiple RNA recognition motif-containing proteins by C9orf72 repeat expansions. Brain . 2014;137(7):2040–2051. .
   Web of Science ®Google Scholar
• Sivadasan R, Hornburg D, Drepper C, et al. C9ORF72 interaction with cofilin modulates actin dynamics in motor neurons. Nat Neurosci. 2016;19(12):1610–1618.
   PubMed Web of Science ®Google Scholar
• Ho WY, Tai YK, and Chang JC, et al. . In: Autophagy. 2019; 15(5):827–42 .
   Web of Science ®Google Scholar
• Farg MA, Sundaramoorthy V, Sultana JM, et al. C9ORF72, implicated in amytrophic lateral sclerosis and frontotemporal dementia, regulates endosomal trafficking. Hum Mol Genet. 2014;23(13):3579–3595.
   PubMed Web of Science ®Google Scholar
• Li Q, Vande VC, Israelson A, et al. ALS-linked mutant superoxide dismutase 1 (SOD1) alters mitochondrial protein composition and decreases protein import. Proc Natl Acad Sci U S A. 2010;107(49):21146–21151.
   PubMed Web of Science ®Google Scholar
• Fukada K, Zhang F, Vien A, et al. Mitochondrial proteomic analysis of a cell line model of familial amyotrophic lateral sclerosis. Mol Cell Proteomics. 2004;3(12):1211–1223.
   PubMed Web of Science ®Google Scholar
• Allen S, Heath PR, Kirby J, et al. Analysis of the cytosolic proteome in a cell culture model of familial amyotrophic lateral sclerosis reveals alterations to the proteasome, antioxidant defenses, and nitric oxide synthetic pathways. J Biol Chem. 2003;278(8):6371–6383.
   PubMed Web of Science ®Google Scholar
• Di Poto C, Iadarola P, Bardoni AM, et al. 2-DE and MALDI-TOF-MS for a comparative analysis of proteins expressed in different cellular models of amyotrophical lateral sclerosis. Electrophoresis. 2007;28(23):4320–4329.
   PubMed Web of Science ®Google Scholar
• Shin JH, London J, Le Pecheur M, et al. Proteome analysis in hippocampus of mice overexpressing human Cu/Zn-superoxide dismutase 1. Neurochem Int. 2005;46(8):641–653.
   PubMed Web of Science ®Google Scholar
• Zhang K, Donnelly CJ, Haeusler AR, et al. The C9orf72 repeat expansion disrupts nucleocytoplasmic transport. Nature. 2015;525(7567):56–61.
   PubMed Web of Science ®Google Scholar
• Ortega JA, Daley EL, Kour S, et al. Nucleocytoplasmic Proteomic Analysis Uncovers eRF1 and Nonsense-Mediated Decay as Modifiers of ALS/FTD C9orf72 Toxicity. Neuron. 2020;106(1):90–107.e13.
   PubMed Web of Science ®Google Scholar
• Štalekar M, Yin X, Rebolj K, et al. Proteomic analyses reveal that loss of TDP-43 affects RNA processing and intracellular transport. Neuroscience. 2015;293:157–170.
   PubMed Web of Science ®Google Scholar
• Kim JE, Hong YH, and Kim JY, et al. Altered nucleocytoplasmic proteome and transcriptome distributions in an in vitro model of amyotrophic lateral sclerosis. PLoS One. 2017; 28(12):e0176462 .
   Web of Science ®Google Scholar
• Wolozin B, Ivanov P. Stress granules and neurodegeneration. Nat Rev Neurosci. 2019;20(11):649–666.
   PubMed Web of Science ®Google Scholar
• Jain S, Wheeler JR, and Walters RW, et al. ATPase-modulated stress granules contain a diverse proteome and substructure. Cell . 2016;164(3):487–498.
   PubMed Web of Science ®Google Scholar
• Fernandes N, Nero L, Lyons SM, et al. Stress granule assembly can facilitate but is not required for TDP‐43 cytoplasmic aggregation. Biomolecules. 2020;10(10):1367.
   Web of Science ®Google Scholar
• Marmor-Kollet H, Siany A, Kedersha N, et al. Spatiotemporal Proteomic Analysis of Stress Granule Disassembly Using APEX Reveals Regulation by SUMOylation and Links to ALS Pathogenesis. Mol Cell. 2020;80(5):876–891.e6.
   PubMed Web of Science ®Google Scholar
• Vu L, Ghosh A, Tran C, et al. Defining the Caprin-1 Interactome in Unstressed and Stressed Conditions. J Proteome Res. 2021;20(6):3165–3178.
   PubMed Web of Science ®Google Scholar
• Turner MR. Progress and new frontiers in biomarkers for amyotrophic lateral sclerosis. Biomark Med. 2018;12(7):693–696.
   PubMed Web of Science ®Google Scholar
• Poesen K, and Van Damme P. Diagnostic and prognostic performance of neurofilaments in ALS. Front. Neurol. 2019; 9 1167 .
   Web of Science ®Google Scholar
• Figlewicz DA, Krizus A, Martinoli MG, et al. Variants of the heavy neurofilament subunit are associated with the development of amyotrophic lateral sclerosis. Hum Mol Genet. 1994;3(10):1757–1761.
   PubMed Web of Science ®Google Scholar
• Steinacker P, Feneberg E, and Weishaupt J, et al. Neurofilaments in the diagnosis of motoneuron diseases: a prospective study on 455 patients. J Neurol Neurosurg Psychiatry . 2016;87(1):12–20.
   PubMed Web of Science ®Google Scholar
• Feneberg E, Oeckl P, and Steinacker P, et al. Multicenter evaluation of neurofilaments in early symptom onset amyotrophic lateral sclerosis. Neurology . 2018;90(1):e22–e30.
   PubMed Web of Science ®Google Scholar
• Lu CH, Macdonald-Wallis C, and Gray E, et al. Neurofilament light chain: a prognostic biomarker in amyotrophic lateral sclerosis. Neurology . 2015;84(22):2247–2257.
   PubMed Web of Science ®Google Scholar
• Ganesalingam J, An J, Shaw CE, et al. Combination of neurofilament heavy chain and complement C3 as CSF biomarkers for ALS. J Neurochem. 2011;117(3):528–537.
   PubMed Web of Science ®Google Scholar
• Turner MR, and Gray E. Are neurofilaments heading for the ALS clinic? J Neurol Neurosurg Psychiatry. . 2016;87(1):3–4.
   PubMed Web of Science ®Google Scholar
• Lewczuk P, Riederer P, and O’Bryant SE, et al. Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: an update of the consensus of the task force on biological markers in psychiatry of the world federation of societies of biological psychiatry. World J Biol Psychiatry . 2018;19(4):244–328.
   PubMed Web of Science ®Google Scholar
• Fairfoul G, McGuire LI, Pal S, et al. Alpha-synuclein RT-Qu IC in the CSF of patients with alpha-synucleinopathies. Ann Clin Transl Neurol. 2016;3(10):812–818.
   PubMed Web of Science ®Google Scholar
• Atarashi R, Sano K, Satoh K, et al. Real-time quaking-induced conversion: a highly sensitive assay for prion detection. Prion. 2011;5(3):150–153.
   PubMed Web of Science ®Google Scholar
• Paganoni S, Cudkowicz M, and Berry JD. Outcome measures in amyotrophic lateral sclerosis clinical trials Clin Investig (Lond) . . 2014;4(7):605–618
   PubMedGoogle Scholar
• Van Eijk RPA, Westeneng HJ, Nikolakopoulos S, et al. Refining eligibility criteria for amyotrophic lateral sclerosis clinical trials. Neurology. 2019;92(5):e451–e460.
   PubMed Web of Science ®Google Scholar
• Turner MR, and Benatar M. Ensuring continued progress in biomarkers for amyotrophic lateral sclerosis. Muscle Nerve. . 2015;51(1):14–18.
   PubMed Web of Science ®Google Scholar
• Winer L, Srinivasan D, and Chun S, et al. SOD1 in cerebral spinal fluid as a pharmacodynamic marker for antisense oligonucleotide therapy. JAMA Neurol . 2013;70(2):201–207.
   PubMed Web of Science ®Google Scholar
• Gendron TF, Chew J, and Jn S, et al. Poly(GP) proteins are a useful pharmacodynamic marker for C9ORF72-associated amyotrophic lateral sclerosis. Sci Transl Med. 2017; 9(38: eaai7866
   Web of Science ®Google Scholar
• Shepheard SR, Wuu J, Cardoso M, et al. Urinary p75 ECD. Neurology. 2017;88(12):1137–1143.
   PubMed Web of Science ®Google Scholar
• Gendron TF, Daughrity LM, Heckman MG, et al. Phosphorylated neurofilament heavy chain: a biomarker of survival for C9ORF 72 -associated amyotrophic lateral sclerosis. Ann Neurol. 2017;82(1):139–146.
   PubMed Web of Science ®Google Scholar
• Benatar M, Zhang L, Wang L, et al. Validation of serum neurofilaments as prognostic and potential pharmacodynamic biomarkers for ALS. Neurology. 2020;95(1):e59–e69.
   PubMed Web of Science ®Google Scholar
• Miller T, Cudkowicz M, Shaw PJ, et al. Phase 1–2 Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS. N Engl J Med. 2020;383(2):109–119.
   PubMed Web of Science ®Google Scholar
• Milligan C, Atassi N, Babu S, et al. Tocilizumab is safe and tolerable and reduces C-reactive protein concentrations in the plasma and cerebrospinal fluid of ALS patients. Muscle Nerve. 2021;64(3):309–320.
   PubMed Web of Science ®Google Scholar
• Guldbrandsen A, Farag Y, Kroksveen AC, et al. CSF-PR 2.0: an interactive literature guide to quantitative cerebrospinal fluid mass spectrometry data from neurodegenerative disorders. Mol Cell Proteomics. 2017;16(2):300–309.
   PubMed Web of Science ®Google Scholar
• Dayon L, Cominetti O, Wojcik J, et al. Proteomes of Paired Human Cerebrospinal Fluid and Plasma: relation to Blood-Brain Barrier Permeability in Older Adults. J Proteome Res. 2019;18(3):1162–1174.
   PubMed Web of Science ®Google Scholar
• Barschke P, Oeckl P, and Steinacker P, et al. Proteomic studies in the discovery of cerebrospinal fluid biomarkers for amyotrophic lateral sclerosis. Expert Rev Proteomics . 2017;14(9):769–777.
   PubMed Web of Science ®Google Scholar
• Ranganathan S, Nicholl GC, and Henry S, et al. Comparative proteomic profiling of cerebrospinal fluid between living and post mortem ALS and control subjects. Amyotroph Lateral Scler . 2007;8(6):373–379.
   PubMed Web of Science ®Google Scholar
• Brettschneider J, Lehmensiek V, Mogel H, et al. Proteome analysis reveals candidate markers of disease progression in amyotrophic lateral sclerosis (ALS). Neurosci Lett. 2010;468(1):23–27.
   PubMed Web of Science ®Google Scholar
• Collins M, Riascos D, Kovalik T, et al. The RNA-binding motif 45 (RBM45) protein accumulates in inclusion bodies in amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration with TDP-43 inclusions (FTLD-TDP) patients. Acta Neuropathol. 2012;124(5):717–732.
   PubMed Web of Science ®Google Scholar
• Bereman MS, Beri J, and Enders JR, et al. Machine Learning Reveals Protein Signatures in CSF and Plasma Fluids of Clinical Value for ALS. Sci Rep. 2018;8(1).
   PubMedGoogle Scholar
• Zhu S, Wuolikainen A, Wu J, et al. Targeted Multiple Reaction Monitoring Analysis of CSF Identifies UCHL1 and GPNMB as Candidate Biomarkers for ALS. J Mol Neurosci. 2019;69(4):643–657.
   PubMed Web of Science ®Google Scholar
• Mellinger AL, Griffith EH, Bereman MS. Peptide variability and signatures associated with disease progression in CSF collected longitudinally from ALS patients. Anal Bioanal Chem. 2020;412(22):5465–5475.
   PubMed Web of Science ®Google Scholar
• Palma AS, De Carvalho M, Grammel N, et al. Proteomic analysis of plasma from Portuguese patients with familial amyotrophic lateral sclerosis. Amyotroph Lateral Scler. 2008;9(6):339–349.
   PubMed Web of Science ®Google Scholar
• Häggmark A, Mikus M, Mohsenchian A, et al. Plasma profiling reveals three proteins associated to amyotrophic lateral sclerosis. Ann Clin Transl Neurol. 2014;1(8):544–553.
   PubMed Web of Science ®Google Scholar
• Ramstrom M, Ivonin I, and Johansson A, et al. Cerebrospinal fluid protein patterns in neurodegenerative disease revealed by liquid chromatography-Fourier transform ion cyclotron resonance mass spectrometry. Proteomics . 2004;4(12)::4010–4018.
   PubMed Web of Science ®Google Scholar
• Collins MA, An J, and Hood BL, et al. Label-Free LC-MS/MS Proteomic Analysis of Cerebrospinal Fluid Identifies Protein/Pathway Alterations and Candidate Biomarkers for Amyotrophic Lateral Sclerosis. J Proteome Res . 2015;14(11):4486–4501.
   PubMed Web of Science ®Google Scholar
• Ranganathan S, Williams E, and Ganchev P, et al. Proteomic profiling of cerebrospinal fluid identifies biomarkers for amyotrophic lateral sclerosis. J Neurochem . 2005;95(5):1461–1471.
   PubMed Web of Science ®Google Scholar
• Pasinetti GM, Ungar LH, and Lange DJ, et al. Identification of potential CSF biomarkers in ALS. Neurology . 2006;66(8):1218–1222.
   PubMed Web of Science ®Google Scholar
• Ryberg H, An J, and Darko S, et al. Discovery and verification of amyotrophic lateral sclerosis biomarkers by proteomics. Muscle Nerve . 2010;42(1):104–111.
   PubMed Web of Science ®Google Scholar
• Sako W, Ishimoto S. Can cystatin C in cerebrospinal fluid be a biomarker for amyotrophic lateral sclerosis? A lesson from previous studies. Neurol Clin Neurosci. 2014;2(3):72–75.
   Google Scholar
• Tsuji-Akimoto S, Yabe I, Niino M, et al. Cystatin C in cerebrospinal fluid as a biomarker of ALS. Neurosci Lett. 2009;452(1):52–55.
   PubMed Web of Science ®Google Scholar
• Thompson AG, Gray E, Bampton A, et al. CSF chitinase proteins in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2019;90(11):1215–1220.
   PubMed Web of Science ®Google Scholar
• Lunetta C, Lizio A, Maestri E, et al. Serum C-reactive protein as a prognostic biomarker in amyotrophic lateral sclerosis. JAMA Neurol. 2017;74(6):660.
   PubMed Web of Science ®Google Scholar
• Beers DR, Zhao W, and Neal DW, et al. Elevated acute phase proteins reflect peripheral inflammation and disease severity in patients with amyotrophic lateral sclerosis. Sci Rep. 2020;10(1).
   Web of Science ®Google Scholar
• Brettschneider J, Mogel H, and Lehmensiek V, et al. Proteome analysis of cerebrospinal fluid in amyotrophic lateral sclerosis (ALS). Neurochem Res . 2008;33(11):2358–2363.
   PubMed Web of Science ®Google Scholar
• Mendonca DM, Pizzati L, and Mostacada K, et al. Neuroproteomics: an insight into ALS. Neurol Res . 2012;34(10):937–943.
   PubMed Web of Science ®Google Scholar
• Wormser U, Mandrioli J, and Vinceti M, et al. Reduced levels of alpha-1-antitrypsin in cerebrospinal fluid of amyotrophic lateral sclerosis patients: a novel approach for a potential treatment. J Neuroinflammation. 2016;13(1).
   PubMedGoogle Scholar
• Von Neuhoff N, Oumeraci T, Wolf T, et al. Monitoring CSF proteome alterations in amyotrophic lateral sclerosis: obstacles and perspectives in translating a novel marker panel to the clinic. PLoS One [Internet]. 2012;7(9):e44401.
   PubMed Web of Science ®Google Scholar
• Chen Y, Liu XH, Wu JJ, et al. Proteomic analysis of cerebrospinal fluid in amyotrophic lateral sclerosis. Exp Ther Med [Internet]. 2016;11(6):2095–2106.
   PubMed Web of Science ®Google Scholar
• Varghese AM, Sharma A, Mishra P, et al. Chitotriosidase - a putative biomarker for sporadic amyotrophic lateral sclerosis. Clin Proteomics [Internet]. 2013;10(1):19.
   PubMed Web of Science ®Google Scholar
• Oeckl P, Weydt P, Steinacker P, et al. Different neuroinflammatory profile in amyotrophic lateral sclerosis and frontotemporal dementia is linked to the clinical phase. J Neurol Neurosurg Psychiatry. 2019;90(1):4–10.
   PubMed Web of Science ®Google Scholar
• Thompson AG, Gray E, Thézénas ML, et al. Cerebrospinal fluid macrophage biomarkers in amyotrophic lateral sclerosis. Ann Neurol. 2018;83(2):258–268.
   PubMed Web of Science ®Google Scholar
• Gray E, Thompson AG, Wuu J, et al. CSF chitinases before and after symptom onset in amyotrophic lateral sclerosis. Ann Clin Transl Neurol. 2020;7(8):1296–1306.
   PubMed Web of Science ®Google Scholar
• Steinacker P, Verde F, Fang L, et al. Chitotriosidase (CHIT1) is increased in microglia and macrophages in spinal cord of amyotrophic lateral sclerosis and cerebrospinal fluid levels correlate with disease severity and progression. J Neurol Neurosurg Psychiatry [Internet]. 2018;89(3):239–247.
   PubMed Web of Science ®Google Scholar
• Gille B, De Schaepdryver M, and Dedeene L, et al. Inflammatory markers in cerebrospinal fluid: independent prognostic biomarkers in amyotrophic lateral sclerosis? J Neurol Neurosurg Psychiatry. 2019;1338–46. .
   PubMed Web of Science ®Google Scholar
• Vu L, An J, Kovalik T, et al. Cross-sectional and longitudinal measures of chitinase proteins in amyotrophic lateral sclerosis and expression of CHI3L1 in activated astrocytes. J Neurol Neurosurg Psychiatry. 2020;91(4):350–358.
   PubMed Web of Science ®Google Scholar
• Varghese AM, Ghosh M, and Bhagat SK, et al. Chitotriosidase, a biomarker of amyotrophic lateral sclerosis, accentuates neurodegeneration in spinal motor neurons through neuroinflammation. J Neuroinflammation. 2020;17(1).
   PubMed Web of Science ®Google Scholar
• Gaur N, Perner C, and Witte OW, et al. The Chitinases as Biomarkers for Amyotrophic Lateral Sclerosis: signals From the CNS and Beyond. Front Neurol. 2020;11.
   PubMed Web of Science ®Google Scholar
• Barschke P, Oeckl P, Steinacker P, et al. Different CSF protein profiles in amyotrophic lateral sclerosis and frontotemporal dementia with C9orf72 hexanucleotide repeat expansion. J Neurol Neurosurg Psychiatry. 2020;91(5):503–511.
   PubMed Web of Science ®Google Scholar
• Thompson AG, Gray E, and Heman-Ackah SM, et al. Extracellular vesicles in neurodegenerative disease - pathogenesis to biomarkers. Nat Rev Neurol . 2016;12(6):346–357.
   PubMed Web of Science ®Google Scholar
• Aoki Y, Manzano R, Lee Y, et al. C9orf72 and RAB7L1 regulate vesicle trafficking in amyotrophic lateral sclerosis and frontotemporal dementia. Brain. 2017;140(4):887–897.
   PubMedGoogle Scholar
• Thompson AG, Gray E, Mager I, et al. UFLC-Derived CSF Extracellular Vesicle Origin and Proteome. Proteomics. 2018;18:1800257.
   PubMed Web of Science ®Google Scholar
• Feneberg E, Steinacker P, and Lehnert S, et al. Limited role of free TDP-43 as a diagnostic tool in neurodegenerative diseases. Amyotroph Lateral Scler Front Degener . 2014;15:351–356. (
   PubMed Web of Science ®Google Scholar
• Thompson AG, Gray E, and Mäger I, et al. CSF extracellular vesicle proteomics demonstrates altered protein homeostasis in amyotrophic lateral sclerosis. Clin Proteomics. 2020;17(1).
   PubMed Web of Science ®Google Scholar
• Hayashi N, Doi H, Kurata Y, et al. Proteomic analysis of exosome-enriched fractions derived from cerebrospinal fluid of amyotrophic lateral sclerosis patients. Neurosci Res. 2019;160:43–49.
   PubMed Web of Science ®Google Scholar
• Mustapic M, Eitan E, and Werner JK, et al. Plasma extracellular vesicles enriched for neuronal origin: a potential window into brain pathologic processes. Front Neurosci. 2017;11.
   PubMed Web of Science ®Google Scholar
• Goetzl EJ, Boxer A, Schwartz JB, et al. Altered lysosomal proteins in neural-derived plasma exosomes in preclinical Alzheimer disease. Neurology. 2015;85(1):40–47.
   PubMed Web of Science ®Google Scholar
• Jiang C, Hopfner F, Hopfner F, et al. Serum neuronal exosomes predict and differentiate Parkinson’s disease from atypical parkinsonism. J Neurol Neurosurg Psychiatry. 2020;91(7):720–729.
   PubMed Web of Science ®Google Scholar
• Norman M, Ter-Ovanesyan D, Trieu W, et al. L1CAM is not associated with extracellular vesicles in human cerebrospinal fluid or plasma. Nat Methods. 2021;18(6):631–634.
   PubMed Web of Science ®Google Scholar
• Benatar M, Wuu J, Andersen PM, et al. Neurofilament light: a candidate biomarker of presymptomatic amyotrophic lateral sclerosis and phenoconversion. Ann Neurol. 2018;84(1):130–139.
   PubMed Web of Science ®Google Scholar
• Vucic S, Nicholson GA, and Kiernan MC. Cortical hyperexcitability may precede the onset of familial amyotrophic lateral sclerosis. Brain. 2008;131(6):1540–1550.
   PubMed Web of Science ®Google Scholar
• Weydt P, Oeckl P, Huss A, et al. Neurofilament levels as biomarkers in asymptomatic and symptomatic familial amyotrophic lateral sclerosis. Ann Neurol. 2016;79(1):152–158.
   PubMed Web of Science ®Google Scholar
• Benatar M, Wuu J. Presymptomatic studies in ALS: rationale, challenges, and approach. Neurology. 2012;79(16):1732–1739.
   PubMed Web of Science ®Google Scholar
• Leoni E, Bremang M, and Mitra V, et al. Combined Tissue-Fluid Proteomics to Unravel Phenotypic Variability in Amyotrophic Lateral Sclerosis. Sci Rep. 2019;9(1).
   PubMedGoogle Scholar
• Zubiri I, Lombardi V, and Bremang M, et al. Tissue-enhanced plasma proteomic analysis for disease stratification in amyotrophic lateral sclerosis. Mol Neurodegener. 2018;13(1).
   PubMedGoogle Scholar
• Conraux L, Pech C, Guerraoui H, et al. Plasma peptide biomarker discovery for amyotrophic lateral sclerosis by MALDI-TOF mass spectrometry profiling. PLoS One. 2013;8(11):e79733.
   PubMed Web of Science ®Google Scholar
• Xu Z, Lee A, Nouwens A, et al. Mass spectrometry analysis of plasma from amyotrophic lateral sclerosis and control subjects. Amyotroph Lateral Scler Front Degener. 2018;19(5–6):362–376.
   PubMed Web of Science ®Google Scholar
• Katzeff JS, Bright F, and Lo K, et al. Altered serum protein levels in frontotemporal dementia and amyotrophic lateral sclerosis indicate calcium and immunity dysregulation. Sci Rep. 2020;10(1) .
   Web of Science ®Google Scholar
• Nardo G, Pozzi S, Mantovani S, et al. Nitroproteomics of peripheral blood mononuclear cells from patients and a rat model of ALS. Antioxid Redox Signal. 2009;11(7):1559–1567.
   PubMed Web of Science ®Google Scholar
• Nardo G, Pozzi S, Pignataro M, et al. Amyotrophic lateral sclerosis multiprotein biomarkers in peripheral blood mononuclear cells. PLoS One. 2011;6(10):e25545.
   PubMed Web of Science ®Google Scholar
• Thompson AG, Gray E, and Charles PD, et al. Network Analysis of the CSF Proteome Characterizes Convergent Pathways of Cellular Dysfunction in ALS. Front Neurosci. 2021;15.
   Web of Science ®Google Scholar
• Higginbotham L, Ping L, Dammer EB, et al. Integrated proteomics reveals brain-based cerebrospinal fluid biomarkers in asymptomatic and symptomatic Alzheimer’s disease. Sci Adv. 2020;6(43):eaaz9360.
   PubMed Web of Science ®Google Scholar
• Aslam B, Basit M, Nisar MA, et al. Proteomics: technologies and their applications. J Chromatogr Sci. 2017;55(2):182–196.
   PubMed Web of Science ®Google Scholar
• Van Damme P, Robberecht W, Van Den Bosch L. Modelling amyotrophic lateral sclerosis: progress and possibilities. DMM Dis Model Mech. 2017;10(5):537–549.
   PubMed Web of Science ®Google Scholar
• Wong CO, Venkatachalam K. Motor neurons from ALS patients with mutations in C9ORF72 and SOD1 exhibit distinct transcriptional landscapes. Hum Mol Genet. 2019;28(16):2799–2810.
   PubMed Web of Science ®Google Scholar
• Morello G, Salomone S, and D’Agata V, et al. From Multi-Omics Approaches to Precision Medicine in Amyotrophic Lateral Sclerosis. Front Neurosci. 2020;14.
   Web of Science ®Google Scholar
• Niehaus M, Soltwisch J, Belov ME, et al. Transmission-mode MALDI-2 mass spectrometry imaging of cells and tissues at subcellular resolution. Nat Methods. 2019;16(9):925–931.
   PubMed Web of Science ®Google Scholar
• Acquadro E, Caron I, Tortarolo M, et al. Human SOD1-G93A specific distribution evidenced in murine brain of a transgenic model for amyotrophic lateral sclerosis by MALDI imaging mass spectrometry. J Proteome Res. 2014;13(4):1800–1809.
   PubMed Web of Science ®Google Scholar
• Xu BJ. Combining laser capture microdissection and proteomics: methodologies and clinical applications. Proteomics - Clin Appl. 2010;4(2):116–123.
   PubMed Web of Science ®Google Scholar
• Schoof EM, Furtwängler B, and Üresin N, et al. Quantitative single-cell proteomics as a tool to characterize cellular hierarchies. Nat Commun. 2021;12(1).
   Web of Science ®Google Scholar
• Gut G, Herrmann MD, and Pelkmans L. Multiplexed protein maps link subcellular organization to cellular states. Science. 2018;361(6401).
   Web of Science ®Google Scholar
• Li KW, Gonzalez-Lozano MA, and Koopmans F, et al. Recent Developments in Data Independent Acquisition (DIA) Mass Spectrometry: application of Quantitative Analysis of the Brain Proteome. Front Mol Neurosci. 2020;13.
   Web of Science ®Google Scholar
• Halvey P, Farutin V, and Koppes L, et al. Variable blood processing procedures contribute to plasma proteomic variability. Clin Proteomics. 2021;18(1).
   PubMed Web of Science ®Google Scholar
• Robelin L, Gonzalez De Aguilar JL. Blood biomarkers for amyotrophic lateral sclerosis: myth or reality? BioMed Res Int. 2014;2014:1–11.
   Web of Science ®Google Scholar
• Carlyle BC, Trombetta BA, Arnold SE. Proteomic approaches for the discovery of biofluid biomarkers of neurodegenerative dementias. Proteomes. 2018;6(3):32.
   PubMed Web of Science ®Google Scholar